National Institutes of Health (NIH) Research 
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.
This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Maternal Mortality: A National Institutes of Health Pathways to Prevention Panel Report
Obstet Gynecol. 2023 Dec 21. doi: 10.1097/AOG.0000000000005488. Online ahead of print.ABSTRACTThe National Institutes of Health's (NIH) Pathways to Prevention panel on postpartum health provides a consensus statement on the evidence, research gaps, and future priorities to prevent maternal morbidity and mortality. The panel reviewed an NIH-commissioned evidence review and workshop that included epidemiologic studies, demonstration interventions, and other maternal morbidity and mortality research to create these national recommendations. The panel concludes that a maternal morbidity and mortality crisis reflects a systemic...
Source: Obstetrics and Gynecology - December 21, 2023 Category: OBGYN Authors: Karina W Davidson Mary Beth Terry Paula Braveman Pamela J Reis Stefan Timmermans John W Epling Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Maternal Mortality: A National Institutes of Health Pathways to Prevention Panel Report
Obstet Gynecol. 2023 Dec 21. doi: 10.1097/AOG.0000000000005488. Online ahead of print.ABSTRACTThe National Institutes of Health's (NIH) Pathways to Prevention panel on postpartum health provides a consensus statement on the evidence, research gaps, and future priorities to prevent maternal morbidity and mortality. The panel reviewed an NIH-commissioned evidence review and workshop that included epidemiologic studies, demonstration interventions, and other maternal morbidity and mortality research to create these national recommendations. The panel concludes that a maternal morbidity and mortality crisis reflects a systemic...
Source: Obstetrics and Gynecology - December 21, 2023 Category: OBGYN Authors: Karina W Davidson Mary Beth Terry Paula Braveman Pamela J Reis Stefan Timmermans John W Epling Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Maternal Mortality: A National Institutes of Health Pathways to Prevention Panel Report
Obstet Gynecol. 2023 Dec 21. doi: 10.1097/AOG.0000000000005488. Online ahead of print.ABSTRACTThe National Institutes of Health's (NIH) Pathways to Prevention panel on postpartum health provides a consensus statement on the evidence, research gaps, and future priorities to prevent maternal morbidity and mortality. The panel reviewed an NIH-commissioned evidence review and workshop that included epidemiologic studies, demonstration interventions, and other maternal morbidity and mortality research to create these national recommendations. The panel concludes that a maternal morbidity and mortality crisis reflects a systemic...
Source: Obstetrics and Gynecology - December 21, 2023 Category: OBGYN Authors: Karina W Davidson Mary Beth Terry Paula Braveman Pamela J Reis Stefan Timmermans John W Epling Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Maternal Mortality: A National Institutes of Health Pathways to Prevention Panel Report
Obstet Gynecol. 2023 Dec 21. doi: 10.1097/AOG.0000000000005488. Online ahead of print.ABSTRACTThe National Institutes of Health's (NIH) Pathways to Prevention panel on postpartum health provides a consensus statement on the evidence, research gaps, and future priorities to prevent maternal morbidity and mortality. The panel reviewed an NIH-commissioned evidence review and workshop that included epidemiologic studies, demonstration interventions, and other maternal morbidity and mortality research to create these national recommendations. The panel concludes that a maternal morbidity and mortality crisis reflects a systemic...
Source: Obstetrics and Gynecology - December 21, 2023 Category: OBGYN Authors: Karina W Davidson Mary Beth Terry Paula Braveman Pamela J Reis Stefan Timmermans John W Epling Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Maternal Mortality: A National Institutes of Health Pathways to Prevention Panel Report
Obstet Gynecol. 2023 Dec 21. doi: 10.1097/AOG.0000000000005488. Online ahead of print.ABSTRACTThe National Institutes of Health's (NIH) Pathways to Prevention panel on postpartum health provides a consensus statement on the evidence, research gaps, and future priorities to prevent maternal morbidity and mortality. The panel reviewed an NIH-commissioned evidence review and workshop that included epidemiologic studies, demonstration interventions, and other maternal morbidity and mortality research to create these national recommendations. The panel concludes that a maternal morbidity and mortality crisis reflects a systemic...
Source: Obstetrics and Gynecology - December 21, 2023 Category: OBGYN Authors: Karina W Davidson Mary Beth Terry Paula Braveman Pamela J Reis Stefan Timmermans John W Epling Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Maternal Mortality: A National Institutes of Health Pathways to Prevention Panel Report
Obstet Gynecol. 2023 Dec 21. doi: 10.1097/AOG.0000000000005488. Online ahead of print.ABSTRACTThe National Institutes of Health's (NIH) Pathways to Prevention panel on postpartum health provides a consensus statement on the evidence, research gaps, and future priorities to prevent maternal morbidity and mortality. The panel reviewed an NIH-commissioned evidence review and workshop that included epidemiologic studies, demonstration interventions, and other maternal morbidity and mortality research to create these national recommendations. The panel concludes that a maternal morbidity and mortality crisis reflects a systemic...
Source: Obstetrics and Gynecology - December 21, 2023 Category: OBGYN Authors: Karina W Davidson Mary Beth Terry Paula Braveman Pamela J Reis Stefan Timmermans John W Epling Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
Maternal Mortality: A National Institutes of Health Pathways to Prevention Panel Report
Obstet Gynecol. 2023 Dec 21. doi: 10.1097/AOG.0000000000005488. Online ahead of print.ABSTRACTThe National Institutes of Health's (NIH) Pathways to Prevention panel on postpartum health provides a consensus statement on the evidence, research gaps, and future priorities to prevent maternal morbidity and mortality. The panel reviewed an NIH-commissioned evidence review and workshop that included epidemiologic studies, demonstration interventions, and other maternal morbidity and mortality research to create these national recommendations. The panel concludes that a maternal morbidity and mortality crisis reflects a systemic...
Source: Obstetrics and Gynecology - December 21, 2023 Category: OBGYN Authors: Karina W Davidson Mary Beth Terry Paula Braveman Pamela J Reis Stefan Timmermans John W Epling Source Type: research
SARS-CoV-2 Rebound With and Without Use of COVID-19 Oral Antivirals
MMWR Morb Mortal Wkly Rep. 2023 Dec 22;72(51):1357-1364. doi: 10.15585/mmwr.mm7251a1.ABSTRACTEarly treatment with a first-line therapy (nirmatrelvir/ritonavir [Paxlovid] or remdesivir) or second-line therapy (molnupiravir) prevents hospitalization and death among patients with mild-to-moderate COVID-19 who are at risk for severe disease and is recommended by the National Institutes of Health COVID-19 Treatment Guidelines. On May 25, 2023, the Food and Drug Administration approved nirmatrelvir/ritonavir for treatment of adults at high risk for severe disease. Although antiviral therapies are widely available, they are under...
Source: MMWR Morb Mortal Wkl... - December 21, 2023 Category: Epidemiology Authors: Dallas J Smith Anastasia Lambrou Pragna Patel Source Type: research
